Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 859 across all filing types
Latest filing 2020-04-01 Proxy Solicitation & In…
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2020-04-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a loan agreement (a financing activity) with details about the credit facility and interest rate provisions. There are no financial statements or comprehensive financial data presented, only a description of the amendment and a reference to the exhibit. The document length is 3430 characters, which is relatively short and consistent with an announcement rather than a full report. The nature of the content is an update on financing activities, specifically an amendment to a loan agreement, which fits the Capital/Financing Update category. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-04-01 English
Regulatory Filings 2020
Regulatory Filings
2020-03-06 English
Board/Management Information 2020
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically details salary increases for certain officers, which falls under changes in senior management compensation. The key section is Item 5.02, which relates to departure or appointment of directors or officers and compensatory arrangements. This matches the category for Board/Management Information (MANG). The document length is short (3106 characters) and contains specific management changes, not a full report or earnings release. Therefore, the correct classification is MANG with high confidence.
2020-03-05 English
FORM 4
Director's Dealing
2020-03-03 English
FORM 4
Director's Dealing
2020-03-03 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.